Current recommanded treatment for advanced NSCLC in first- and higher- line setting are based on the presence of genetic aberrations, such as the strong recommandation of EGFR-TKIs for pateints bearing EGFR sensitizing mutations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.